Identifying new piperazine-based PARP1 inhibitors using text mining and integrated molecular modeling approaches

References

• Banks, J. L., Beard, H. S., Cao, Y., Cho, A. E., Damm, W., Farid, R., … Levy, R. M. (2005). Integrated Modeling Program, Applied Chemical Theory (IMPACT). Journal of Computational Chemistry, 26(16), 1752–1780. doi:10.1002/jcc.20292
   PubMed Web of Science ®Google Scholar
• Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., & Hermans, J. (1981). Interaction models for water in relation to protein hydration (pp. 331–342). Springer Netherlands, Dordrecht.
   Google Scholar
• Burkle, A., Diefenbach, J., Brabeck, C., & Beneke, S. (2005). Ageing and PARP. Pharmacological Research, 52(1), 93–99. doi:10.1016/j.phrs.2005.02.008
   PubMed Web of Science ®Google Scholar
• Curtin, N. J., & Szabo, C. (2013). Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. Molecular Aspects of Medicine, 34(6), 1217–1256. doi:10.1016/j.mam.2013.01.006
   PubMed Web of Science ®Google Scholar
• Ekblad, T., Camaioni, E., Schuler, H., & Macchiarulo, A. (2013). PARP inhibitors: Polypharmacology versus selective inhibition. FEBS Journal, 280(15), 3563–3575. doi:10.1111/febs.12298
   PubMed Web of Science ®Google Scholar
• Ekhteiari Salmas, R., Unlu, A., Bektaş, M., Yurtsever, M., Mestanoglu, M., & Durdagi, S. (2017). Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: Combination of in silico and in vitro studies. Journal of Biomolecular Structure and Dynamics, 35(9), 1899–1915. doi:10.1080/07391102.2016.1199328
   PubMed Web of Science ®Google Scholar
• Ekhteiari Salmas, R., Unlu, A., Yurtsever, M., Noskov, S. Y., & Durdagi, S. (2016). In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(1), 112–120. doi:10.3109/14756366.2015.1005011
   PubMed Web of Science ®Google Scholar
• Ekhteiari Salmas, R., Senturk, M., Yurtsever, M., & Durdagi, S. (2016). Discovering novel carbonic anhydrase type IX (CA IX) inhibitors from seven million compounds using virtual screening and in vitro analysis. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(3), 425–433. doi:10.3109/14756366.2015.1036049
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., … Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749. doi:10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Graziani, G., Battaini, F., & Zhang, J. (2005). PARP-1 inhibition to treat cancer, ischemia, inflammation. Pharmacological Research, 52(1), 1–4. doi:10.1016/j.phrs.2005.02.007
   PubMed Web of Science ®Google Scholar
• Hoover, W. G. (1985). Canonical dynamics: Equilibrium phase-space distributions. Physical Review A, 31(3), 1695–1697. doi:10.1103/PhysRevA.31.1695
   PubMed Web of Science ®Google Scholar
• Hottiger, M. O., Hassa, P. O., Luscher, B., Schuler, H., & Koch-Nolte, F. (2010). Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends in Biochemical Sciences, 35(4), 208–219. doi:10.1016/j.tibs.2009.12.003
   PubMed Web of Science ®Google Scholar
• Hou, T., Wang, J., Li, Y., & Wang, W. (2011). Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. Journal of Chemical Information and Modeling, 51(1), 69–82. doi:10.1021/ci100275a
   PubMed Web of Science ®Google Scholar
• Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J., Honig, B., Shaw, D. E., & Friesner, R. A. (2004). A hierarchical approach to all-atom protein loop prediction. Proteins: Structure, Function, and Bioinformatics, 55(2), 351–367. doi:10.1002/prot.10613
   PubMed Web of Science ®Google Scholar
• Johannes, J. W., Almeida, L., Daly, K., Ferguson, A. D., Grosskurth, S. E., Guan, H., … Scott, D. A. (2015). Discovery of AZ0108, an orally bioavailable phthalazinone PARPinhibitor that blocks centrosome clustering. Bioorganic & Medicinal Chemistry Letters, 25(24), 5743–5747. doi:10.1016/j.bmcl.2015.10.079
   PubMed Web of Science ®Google Scholar
• Jeggo, P. A. (1998). DNA repair: PARP - another guardian angel? Current Biology, 8(2), 49–51.
   Web of Science ®Google Scholar
• Kanan, T., Kanan, D., Erol, I., Yazdi, S., Stein, M., & Durdagi, S. (2019). Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models. Journal of Molecular Graphics and Modelling, 86, 264–277. doi:10.1016/j.jmgm.2018.09.014
   PubMed Web of Science ®Google Scholar
• Krallinger, M., & Valencia, A. (2005). Text-mining and information-retrieval services for molecular biology. Genome Biology, 6(7), 224. [PubMed Central:PMC1175978] [ [PubMed:12501816]. [Mismatch] doi:10.1186/gb-2005-6-7-224]
   PubMed Web of Science ®Google Scholar
• Kraus, W. L., & Hottiger, M. O. (2013). PARP-1 and gene regulation: Progress and puzzles. Molecular Aspects of Medicine, 34(6), 1109–1123. doi:10.1016/j.mam.2013.01.005
   PubMed Web of Science ®Google Scholar
• Li, J., Abel, R., Zhu, K., Cao, Y., Zhao, S., & Friesner, R. A. (2011). The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. Proteins: Structure, Function, and Bioinformatics, 79(10), 2794–2812. doi:10.1002/prot.23106
   PubMed Web of Science ®Google Scholar
• Liscio, P., Camaioni, E., Carotti, A., Pellicciari, R., & Macchiarulo, A. (2013). From polypharmacology to target specificity: The case of PARP inhibitors. Current Topics in Medicinal Chemistry, 13(23), 2939–2954. doi:10.2174/15680266113136660209
   PubMed Web of Science ®Google Scholar
• Lord, C. J., & Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the clinic. Science, 355(6330), 1152–1158. doi:10.1126/science.aam7344
   PubMed Web of Science ®Google Scholar
• Luo, X., & Kraus, W. L. (2012). On PAR with PARP: Cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes & Development, 26(5), 417–432. doi:10.1101/gad.183509.111
   PubMed Web of Science ®Google Scholar
• Ma, Z., & Tuckerman, M. (2010). Constant pressure ab initio molecular dynamics with discrete variable representation basis sets. Journal of Chemical Physics., 133(18), 184110. doi:10.1063/1.3499812
   PubMed Web of Science ®Google Scholar
• Megnin-Chanet, F., Bollet, M. A., & Hall, J. (2010). Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cellular and Molecular Life Sciences, 67(21), 3649–3662. doi:10.1007/s00018-010-0490-8
   PubMed Web of Science ®Google Scholar
• Michels, J., Vitale, I., Saparbaev, M., Castedo, M., & Kroemer, G. (2014). Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene, 33(30), 3894–3907. doi:10.1038/onc.2013.352
   PubMed Web of Science ®Google Scholar
• Mirza, S. B., Salmas, R. E., Fatmi, M. Q., & Durdagi, S. (2016). Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study. Journal of Molecular Graphics and Modelling, 66, 99–107. doi:10.1016/j.jmgm.2016.03.008
   PubMed Web of Science ®Google Scholar
• Morikawa, A., & Henry, N. L. (2015). Palbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer. Clinical Cancer Research, 21(16), 3591–3596. doi:10.1158/1078-0432.CCR-15-0390
   PubMed Web of Science ®Google Scholar
• O’Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., … Druker, B. J. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348(11), 994–1004. doi:10.1056/NEJMoa022457
   PubMed Web of Science ®Google Scholar
• Ogata, N., Ueda, K., Kawaichi, M., & Hayaishi, O. (1981). Poly(ADP-ribose) synthetase, a main acceptor of poly(ADP-ribose) in isolated nuclei. The Journal of Biological Chemistry, 256(9), 4135–4137.
   PubMed Web of Science ®Google Scholar
• Pavlovsky, C., Chan, O., Talati, C., & Pinilla-Ibarz, J. (2019). Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Future Oncology, 15(3), 257–269. doi:10.2217/fon-2018-0371
   PubMed Web of Science ®Google Scholar
• Plummer, R. (2014). Poly(ADP-ribose)polymerase (PARP) inhibitors: From bench to bedside. Clinical Oncology), 26(5), 250–256. doi:10.1016/j.clon.2014.02.007
   Web of Science ®Google Scholar
• Raha, K., & Merz, K. M. (2004). A quantum mechanics-based scoring function: Study of zinc ion mediated ligand binding. Journal of the American Chemical Society, 126(4), 1020–1021. doi:10.1021/ja038496i
   PubMed Web of Science ®Google Scholar
• Sahin, K., Zengin Kurt, B., Sonmez, F., & Durdagi, S. (2019). Novel AChE and BChE inhibitors using combined virtual screening, text mining and in vitro binding assays. Journal of Biomolecular Structure and Dynamics. (In press). doi:10.1080/07391102.2019.1660218
   Web of Science ®Google Scholar
• Satoh, M. S., & Lindahl, T. (1992). Role of poly(ADP-ribose) formation in DNA repair. Nature, 356(6367), 356–358. doi:10.1038/356356a0
   PubMed Web of Science ®Google Scholar
• Schreiber, V., Dantzer, F., Ame, J. C., & de Murcia, G. (2006). Poly(ADP-ribose): Novel functions for an old molecule. Nature Reviews Molecular Cell Biology, 7(7), 517–528. doi:10.1038/nrm1963
   PubMed Web of Science ®Google Scholar
• Scott, L. J. (2017). Niraparib: First global approval. Drugs, 77(9), 1029–1034.
   PubMed Web of Science ®Google Scholar
• Shaquiquzzaman, M., Verma, G., Marella, A., Akhter, M., Akhtar, W., Khan, M. F., … Alam, M. M. (2015). Piperazine scaffold: A remarkable tool in generation of diverse pharmacological agents. European Journal of Medicinal Chemistry, 102, 487–529. doi:10.1016/j.ejmech.2015.07.026
   PubMed Web of Science ®Google Scholar
• Shelley, J. C., Cholleti, A., Frye, L. L., Greenwood, J. R., Timlin, M. R., & Uchimaya, M. (2007). Epik: A software program for pK (a) prediction and protonation state generation for drug-like molecules. Journal of Computer-Aided Molecular Design, 21(12), 681–691. doi:10.1007/s10822-007-9133-z
   PubMed Web of Science ®Google Scholar
• Singh, S. S., Sarma, J. A., Narasu, L., Dayam, R., Xu, S., & Neamati, N. (2014). A review on PARP1 inhibitors: Pharmacophore modeling, virtual and biological screening studies to identify novel PARP1 inhibitors. Current Topics in Medicinal Chemistry, 14(17), 2020–2030. doi:10.2174/1568026614666140929152123
   PubMed Web of Science ®Google Scholar
• Śledź, P., & Caflisch, A. (2018). Protein structure-based drug design: From docking to molecular dynamics. Current Opinion in Structural Biology, 48, 93–102. doi:10.1016/j.sbi.2017.10.010
   PubMed Web of Science ®Google Scholar
• Sodhi, R. K., Singh, N., & Jaggi, A. S. (2010). Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications. Vascular Pharmacology, 53(3-4), 77–87. doi:10.1016/j.vph.2010.06.003
   PubMed Web of Science ®Google Scholar
• Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., … Elmore, S. W. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 19(2), 202–208. doi:10.1038/nm.3048
   PubMed Web of Science ®Google Scholar
• Steffen, J. D., Brody, J. R., Armen, R. S., & Pascal, J. M. (2013). Structural implications for selective targeting of PARPs. Frontiers in Oncology, 3, 301doi:10.3389/fonc.2013.00301
   PubMedGoogle Scholar
• Szabo, C. (2005). Cardioprotective effects of poly(ADP-ribose) polymerase inhibition. Pharmacological Research, 52(1), 34–43.
   PubMed Web of Science ®Google Scholar
• Zeng, S., Liu, W., Nie, F. F., Zhao, Q., Rong, J. J., Wang, J., … Guo, Q. L. (2009). LYG-202, a new flavonoid with a piperazine substitution, shows antitumor effects in vivo and in vitro. Biochemical and Biophysical Research Communications, 385(4), 551–556. doi:10.1016/j.bbrc.2009.05.099
   PubMed Web of Science ®Google Scholar